Aptose's TUS Achieves 100% Clinical Response in AML Treatment at Higher Doses
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Significant Efficacy: In newly diagnosed AML patients, the combination of TUS with VEN and AZA achieved a 100% complete response (CR/CRh) rate at the 80mg and 120mg doses, demonstrating the therapy's robust efficacy across diverse mutation backgrounds, which could transform AML treatment paradigms.
- Outstanding Safety: The TUS combination therapy showed no dose-limiting toxicities (DLTs) across all evaluable dose levels, indicating that the treatment is not only effective but also safe, providing a new option for AML patients, particularly those resistant to conventional therapies.
- High MRD Negativity Rate: Among treated patients, 78% achieved minimal residual disease (MRD) negativity as confirmed by central flow cytometry, highlighting the therapy's effectiveness in eliminating cancer cells and potentially offering better long-term survival prospects for patients.
- Clinical Trial Progress: The ongoing TUSCANY trial by Aptose shows that TUS exhibits good anti-leukemic activity at various doses, with preliminary results at the 160mg dose indicating early MRD negativity in patients, further validating the drug's potential.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What factors contribute to the 100% response rate in AML treatment?
How does the TUS triplet therapy achieve high MRD negativity rates?
Will the TUS triplet therapy become a standard treatment for AML patients?
How might the TUS therapy impact survival rates in AML patients long-term?